What was your talk about?

My talk is really an overview of currently what we’re doing in the treatment in both neoadjuvant and metastatic triple negative breast cancer and then what’s coming up on the horizon. So really in the neoadjuvant space, chemotherapy in combination with immunotherapy being the new standard of care in stage 2 and 3 triple negative breast cancer. 

Then in metastatic triple negative breast cancer we’ve come a long way from just chemotherapy to now the use of immunotherapy and antibody-drug conjugates as part of our treatment regimen.

What advances can we expect in the future?

Definitely. In the neoadjuvant space there’s a lot of work looking at how we can de-escalate therapy, potentially being able to eliminate the need for anthracyclines and using other chemo combinations with immunotherapy. In the metastatic setting various combinations of immunotherapy with antibody-drug conjugates, even in the first-line setting. So a lot of exciting advancements in the near future for sure.